HOME >> BIOLOGY >> NEWS
Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion

used to deliver cytokines to diseased target cells without the toxicities observed when cytokines are administered systemically.

Targeted Genetics has supported two Phase I studies of HIV-specific CTLs in HIV infected patients conducted by Riddell and Greenberg at the Hutchinson Center. Additional Phase I/II studies of adoptive immunotherapy using CTLs expanded with the REM technology are ongoing at the Hutchinson Center for the precaution of cytomegalovirus (CMV) disease in bone marrow transplant patients and for the treatment of patients with late stage melanoma Targeted Genetics has several issued and pending patents in this area. Prior to development of the REM technology, technical and regulatory hurdles made adoptive immunotherapy too costly for commercialization. Targeted Genetics has further developed this technology to facilitate commercial development by focusing on scalability of costs and reagents. Targeted Genetics has filed additional patents regarding improvements to the REM technology.

"In addition to its significant potential in adoptive immunotherapy, Targeted Genetics' REM technology also is a strategic core technology for research, development, and commercialization of other technologies aimed at treating chronic viral and malignant disease," said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. "The REM process is applicable to broad-based technologies such as genomics and to the identification of new proteins or small molecules with therapeutic potential. This patent, in concert with Targeted Genetics' other patents and intellectual property, forms a powerful core technology platform either as a stand alone therapeutic or in concert with existing technologies."

Targeted Genetics Corporation develops gene and cell therapy products for the treatment of certain acquired and inherited diseases. The company has three lead development programs targeting cystic fibrosis, cancer, and infectious disease
'"/>

Contact: Susan Edmonds
sedmonds@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
27-Oct-1998


Page: 1 2 3

Related biology news :

1. Intel and Fred Hutchinson to explore the use of nanotechnology tools for early disease detection
2. American Association for Cancer Research honors Fred Hutchinson Cancer Research Center investigator
3. Fred Hutchinson Cancer Research Center, University of Washington join in national effort to study health impact of toxic substances
4. Hutchinson Center researchers first to induce state of suspended animation in model vertebrate organism
5. Digging for genetic fossils: Hutchinson Center researchers solve structure of ancient biological molecule
6. Fred Hutchinson Cancer Research Center to lead international team to accelerate investigation of immune-related genes
7. Hutchinson Center researcher awarded Block lectureship
8. White House honors Hutchinson Center Scientist with Presidential Early Career Award
9. Hutchinson Center to lead $11.5 million ovarian-cancer research consortium
10. Fred Hutchinson Cancer Research Center researcher one of five awarded $1 million distinguished young scholars grant
11. Hutchinson Center Director Wins Americas Nobel

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
(Date:1/24/2017)... PHILADELPHIA , Jan. 24, 2017  It ... a baby,s sock that monitors vital signs and ... instance, an infant,s oxygen saturation level drops. But ... undue alarm to parents, with no evidence of ... "These devices are marketed aggressively to parents of ...
(Date:1/18/2017)... ROCKVILLE, Md. , Jan. 18, 2017  In ... with respect to mergers and acquisitions (M&A), and Kalorama ... reasons for such acquisitions have been shifting. Generally, uncertainty ... and the U.S. has changed the acquisitions ... situation has resulted in companies buying partners outside of ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... business in Hong Kong. , Nerium International is proud to introduce its Age-Defying ... Contour Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products ...
(Date:2/17/2017)... PUNE, India , February 17, 2017 /PRNewswire/ ... research report "Biomarkers Market by Product (Consumables, Service), ... Disorders), Application (Diagnostics Development, Drug Discovery and Development, ... MarketsandMarkets, the market is projected to reach USD ... in 2016, growing at a CAGR of 13.8% ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
Cached News: